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Background: Circumferential pulmonary vein isolation (PVI) is the cornerstone of the current state-of-the-art
management of atrial fibrillation (AF). However, the precise mechanisms behind AF relapses post PVI are still
unknown. Since the activity of the autonomous nervous system is crucial in triggering paroxysmal AF, we
hypothesized that PVI is associated with changes of cardiac sympathetic activity.
Methods: Sixteen patients with paroxysmal AF underwent cardiac iodine-123-meta-iodobenzylguanidine (123I-mIBG)
planar cardiac imaging and single-photon emission computed tomography with low-dose computed tomography
(SPECT/CT) for attenuation correction before and 4 weeks after PVI. The heart-to-mediastinum ratio (H/M ratio),
washout rate (WR), regional myocardial uptake, and regional washout were analyzed.
Results: The late H/M ratio was unchanged by PVI (pre, 2.9 ± 0.5 vs. post, 2.7 ± 0.6, p = 0.53). Four of the 16 patients
(25%) displayed regional deficits before PVI. After PVI, regional deficits were present in ten patients (62.5%) with
newly emerging deficits localized in the inferolateral wall. In a 6-month follow-up, four out of the ten patients (40%)
with regional 123I-mIBG defects suffered from a recurrence of AF, while only one of the six patients (16.7%) without
a regional 123I-mIBG defect experienced a recurrence.
Conclusion: A significant number of patients with paroxysmal AF show regional cardiac sympathetic innervation
deficits at baseline. In addition, PVI is associated with newly emerging defects. The presence of regional
sympathetic denervation after PVI may correlate with the risk of AF relapses.
Keywords: Atrial fibrillation; Pulmonary vein isolation; Sympathetic nervous system; Imaging; Single-photon
emission computed tomographyBackground
Atrial fibrillation (AF) is the most common arrhythmia in
industrialized countries with an increasing burden of mor-
bidity. Circumferential pulmonary vein isolation (PVI) is a
cornerstone of modern AF management showing success
rates of up to 60 to 70% [1,2]. However, a significant num-
ber of patients suffer from a relapse of AF after PVI [2,3].
Clinical parameters such as the type of AF, age, and the* Correspondence: cwenning@uni-muenster.de
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AF patients. However, the prediction for the individual
patient is not yet established in clinical algorithms [1].
Advanced imaging methods such as delayed enhancement
magnetic resonance imaging of the left atrium are cur-
rently being developed but are cumbersome and have not
yet been tested in large multicenter clinical trials [4-7].
Alternative imaging modalities might provide novel
insights into the mechanisms that orchestrate relapses in
patients with AF and may be helpful for the prediction of
the individual outcome following PVI. Besides fibrosis,
sympathetic cardiac innervation seems to play an import-
ant role in the pathogenesis of AF [8,9]. Cardiac single-
photon emission computed tomography (SPECT) imagingis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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mIBG) has been successfully employed to assess cardiac
sympathetic nervous function in various clinical scenarios
[10-12]. Data from small clinical studies suggest that 123I-
mIBG imaging in patients with paroxysmal AF could sup-
port clinical risk stratification. In a recent study, a reduced
H/M ratio for 123I-mIBG has been identified as a predictor
for the development of permanent AF and heart failure
associated with permanent AF [8]. Arimoto et al. demon-
strated that a high global washout rate (WR) of 123I-mIBG
(5 days after PVI) is an independent predictor of AF
relapses following PVI in patients with either paroxysmal
or permanent AF [9]. As a potential limitation, these stud-
ies analyzed the global parameters from planar imaging
(H/M ratio and WR) only. Therefore, we hypothesized
that PVI is not only associated with global but also with
regional changes of the cardiac sympathetic activity. Here,
we describe a prospective series of 16 patients withTable 1 Individual patients characteristics
Individual
number







1 F 51 2 One vessel
CHD
99 Sotalol
2 M 55 10 No CHD 122 Beta blo
3 F 67 7 No CHD 123 Beta blo
droneda
4 M 44 13 No CHD 72 Beta blo
5 F 56 4 No CHD 118 Beta blo
flecainid
6 M 54 1 No CHD 76 Beta blo
flecainid
7 M 72 17 No CHD 82 Beta blo
droneda
8 M 69 3 three vessel
CHD
183 Beta blo
9 M 64 2 No CHD 125 Beta blo
flecainid
10 F 49 5 No CHD 82 Beta blo
flecainid
11 M 48 1 No CHD 116 Beta blo
droneda
12 F 70 2 No CHD N/A Beta blo
droneda
13 M 52 5 No CHD 103 Beta blo
flecainid
14 M 40 1 No CHD 52 Beta blo
15 M 61 4 No CHD 115 Beta blo
flecainid
16 M 52 5 No CHD 103 Beta blo
flecainid
CHD, chronic ischemic heart disease; LA, left atrium; AA, antiarrhythmic, N/A not apparoxysmal AF who underwent serial 123I-mIBG SPECT/
CT imaging before and 4 weeks after PVI and were
followed up for AF relapses.
Methods
Patients
We included 16 consecutive patients (11 men, 5 women)
with paroxysmal AF referred to our clinic for PVI who
received serial 123I-mIBG SPECT/CT. Patients were
between 40 and 72 years old and received standard antiar-
rhythmic therapy including beta blockers, flecainide, and
dronedarone which was mostly continued after PVI as a
prophylactic therapy (patients characteristics, Table 1).
Except the two individuals, no history of coronary artery
disease was known. These two individuals had no history
of myocardial infarction, had normal left ventricular
ejection fraction (>55%), and stress-induced myocardial
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(one patient). The local institutional ethical committee on
human research approved the evaluation and presentation
of the patient data. Informed consent was given by the
patients.Radionuclide (123I-mIBG) imaging
According to a proposal for standardization of 123I-mIBG
cardiac sympathetic imaging by the EANM Cardiovascular
Committee and the European Council of Nuclear
Cardiology [13], all patients received 370 MBq of
123I-mIBG (AdreView, GE Healthcare, Little Chalfont,
Buckinghamshire, UK) and underwent anterior planar
imaging of the thorax SPECT/CT imaging of the heart
at 15 min and 4 h post injection. Data acquisition was
performed on a hybrid two-slice SPECT/CT device
(Symbia T2, Siemens Medical Solutions, Malvern, PA,
USA). Emission data were acquired with parallel-hole,
medium-energy, high-resolution collimators, the two
detector heads positioned in a 90° angle, with a 20%
symmetric energy window centered at 159 keV. Further
acquisition parameters were 32 rotation steps, with 2.8°
rotation per stop, 90° each head, and 25 s per rotational
projection. All SPECT data were acquired electrocardio-
gram (ECG)-gated (eight ECG gates). The left ventricular
end-systolic and end-diastolic volumes (ESV, EDV) and
left ventricular ejection fraction (LVEF) were automatic-
ally calculated from the ECG-gated SPECT data of the
late (4 h p.i.) study by means of the Corridor 4D-
MSPECT software package (version 5.1, INVIA Medical
Imaging Solutions, Ann Arbor, MI, USA). All SPECT
data were corrected for attenuation by CT-attenuation
correction through a low-dose spiral CT scan performed
directly after acquisition of the emission data. CT scans
were acquired during free breathing without ECG-gating,
at spiral mode with pitch 1.4, tube voltage of 130 kV, 30
mAs, scan time 14.67 s, CTDI (computed tomography
dose index) of approximately 3.2, and DLP (dose-length
product) of 55. The CT images were reconstructed at a
5.0-mm thickness by using a reconstruction algorithm
with a 512 × 512 matrix and a full-chest-size-adapted
FOV of 50 × 50 cm2.Analysis
Analysis of planar images
The H/M ratio was determined from the counts/pixel in
a visually drawn heart region of interest (ROI) divided
by the counts/pixel in a visually drawn mediastinum
ROI in the midline upper chest positioned to reflect the
region with lowest background activity, for the early im-
ages as well as for the late images. The mediastinal ROI
had a standardized size of 1,200 mm2. The global WR
was calculated as described elsewhere [13].SPECT analysis
For semiquantitative SPECT image analysis, only
attenuation-corrected early/late images were analyzed by
using the Corridor 4D-MSPECT software package
(version 5.1, INVIA Medical Imaging Solutions, Ann
Arbor, MI, USA). Images were resliced into short and
horizontal/vertical long axis slices for clinical reading.
Additionally, bull's eye plots and a 17-segment model of
the left ventricle were calculated for each SPECT images
set. All images were interpreted by two experienced and
independent nuclear cardiologists blinded to the clinical
data. Each reader scored all SPECT image sets: relative
regional tracer uptake in relation to the maximum
regional myocardial 123I-mIBG uptake was classified using
a 17-segment model of the left ventricle and a semiquanti-
tative five-point scale (0 = normal uptake, 1 =mildly re-
duced uptake, 2 =moderately reduced uptake, 3 = severely
reduced uptake and 4 = absent uptake), as previously
described [14-16]. A ‘summed defect score’ (SDS) was
calculated as the sum of all segmental defect scores in the
late study (4 h p.i.). A SDS ≥ 3 was considered to be an
innervation deficit. In case a single abnormal segment
showed a defect score of 1 or 2, at least two abnormal
segments had to be adjacent to each other to account for
an SDS ≥ 3. Segments showing a score of 3 or 4 did not
necessarily need to be adjacent. For quantitative SPECT
analysis, a 17-segment model of the left ventricle was
calculated by means of a contour finding algorithm, devel-
oped and validated by our group and previously published
(ESM, elastic surface model [17]). Left ventricular segmen-
tation was performed automatically. Segmental 123I-mIBG
washout was calculated as the difference of the percentage
123I-mIBG uptakes between the early (15 min p.i.) and late
(4 h p.i.) SPECT images. Segmental left ventricular 123I-
mIBG uptake and washout (before PVI vs. after PVI) were
compared statistically.
Computed tomography
CT angiography of the atria and pulmonary veins was per-
formed in 15 out of 16 patients for preinterventional of
PVI. All CT examinations were acquired using dual-source
CT systems (either Somatom Definiton or Somatom
Definiton Flash, Siemens Medical Solutions, Malvern, PA,
USA). Examinations were performed at 100 kV according
to a non-ECG-triggered high-pitch (3,2) protocol. Collima-
tion was 64 × 0.6 mm2 for the Somatom Definition and
128 × 0.6 mm2 for the Somatom Definition Flash. A total
of 60 ml of non-ionic, iodinated contrast agent (Ultravist
370, Bayer-Schering-Pharma, Berlin, Germany) was injected
through a right antecubital vein at a flow rate of 5 ml/s,
followed by a 50-ml saline chaser bolus at the same flow
rate. Data acquisition was initiated by a bolus-triggering
technique (CARE Bolus, Siemens Medical Solutions) with
the region of interest placed within the left atrium. The
Wenning et al. EJNMMI Research 2013, 3:81 Page 4 of 10
http://www.ejnmmires.com/content/3/1/81threshold above the native reference scan and the delay be-
fore scanning started were 100 HU respectively 6 s for the
Somatom Definition and 150 HU respective 10 s for the
Somatom Definition Flash. Measurements of the left atrial
size were performed on transverse 1-mm slices with a re-
construction increment of 1 mm using commercially avail-
able software (SyngoVolumetry, Siemens Medical Systems,
Malvern, PA, USA). If ECG-trigger was available (1 case), a
diastolic reconstruction interval was chosen by ECG; other-
wise, the diastole (11 cases) was identified by evaluation of
the valve's status. The pulmonary veins were excluded from
the atrial volume.
Pulmonary vein isolation
PVI was carried out as described previously [3,18]. All
patients signed written informed consent and trans-
esophageal echocardiography was performed in all
patients prior to the procedure. The ablation was per-
formed in the fasting state under sedation with midazo-
lam and pain medication with piritramide as needed.
Surface ECG and endocardial electrograms were con-
tinuously monitored on a computer-based digital ampli-
fier/recorder system (Siemens Axiom Sensis XP or
Prucka, GE Medical Systems Inc., Milwaukee, WI, USA).
Two 6-F sheaths were placed in the left groin. A decapo-
lar steerable catheter (St. Jude Medical, Inc., St. Paul,
MN, or Inquiry, IBI, Irvine Biomedical, Inc., Irvine, CA,
USA) was placed in the coronary sinus via one of the
sheaths. Two 8-F sheaths were placed in the right groin,
one being an SL1-sheath (Daig SL1, St. Jude Medical,
Inc., Little Canada, MN, USA) for transseptal puncture.
Selective angiography of the PV was performed with
about 40 ml of non-ionic contrast (Ultravist 370, Bayer,
Berlin, Germany), in posterior-anterior and left anterior
oblique 60° projections. The 3D geometry of the left
atrium was acquired using the Ensite NavX Velocity (St.
Jude Medical) or the CARTO System (Biosense Webster,
Diamond Bar, CA, USA) or the NaVX-Fusion System
(St. Jude Medical, Inc.). The acquired geometry was
fused with the left atrial 3D reconstruction of theFigure 1 Mean late H/M ratios and global WRs. Late H/M ratios (A) and
sympathetic innervation.computed tomographic (CT) data, previously performed
with the Ensite Verismo software. Thereafter, an antral
point-by-point circumferential ablation around the ipsi-
lateral PV, with a distance of 0.5 to 1.0 cm from the
ostia, using a 4-mm open-tip irrigated catheter (IBI
Therapy Coolpath Duo 7-Fr, St. Jude Medical), was per-
formed. The maximum power was set to 30 W, going
selectively up to 40 W if the PV isolation could not be
achieved, especially at the anterior ridge border of the
lateral PVs. Temperature was limited to 43°C. Irrigation
was adjusted manually between 17 and 30 ml/min. The
complete electrical isolation was monitored and con-
firmed by the decapolar catheter during sinus rhythm
and differential pacing maneuvers.
Statistics
Values are expressed as mean ± standard deviation.
Differences in mean values were compared by either a
Wilcoxon test or a Mann–Whitney U test for unpaired
samples. A p < 0.05 indicated a statistically significant
difference. All statistical analyses were performed using
a commercially available software package (SPSS, version
17.0, SPSS Inc., Chicago IL, USA).
Results
Cardiac sympathetic activity before and after PVI
Analysis of global sympathetic cardiac innervation
Mean late H/M ratios and global WRs did not change
from baseline to the follow-up scan after PVI (pre, 2.9 ±
0.5 vs. post, 2.7 ± 0.6, p = 0.53 and pre, 26.8% ± 6.0% vs.
post, 26.9% ± 3.6%, p = 0.67, respectively; Figure 1A,B).
Analysis of regional sympathetic cardiac innervation
At baseline, no regional defects were observed in the
early (15 min p.i.), except in four patients (25%) in the
late (4 h p.i.) SPECT images. These defects were located
in the inferolateral (three patients) or the lateral wall
(one patient). After PVI, regional deficits were present in
two patients in the early but in the ten patients (62.5%)
in the late images including the four patients withglobal WR (B) before and after PVI indicate no changes in global
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emerging defects post PVI were localized in the infero-
lateral (four patients) and the apical or basal posterior
wall (one patient each), respectively (patient example,
Figure 2). Semiquantitative analysis of all subjects
showed a significant increase in the mean summed de-
fect score (4 h p.i.) from baseline to post PVI (pre, 0.8 ±
1.3 vs. post, 2.6 ± 2.7, p = 0.011; Figure 3). The quantita-
tive SPECT analysis comparing the late (4 h p.i.) 123I-
mIBG uptake before and after PVI showed a significant
reduction of uptake in the left ventricular segments 4, 5,
and 10 and a significantly increased regional washout
in the segments 3, 4, 5, and 11 (Figure 4). In contrast,
H/M ratios did not differ significantly between patients
with (n = 10) and patients without regional defects
(n = 6) after PVI (2.8 ± 0.6 vs. 2.7 ± 0.7, p = not signifi-
cant (ns)). Accordingly, global WRs were similar be-
tween these both groups (26.8% ± 5.0% vs. 27.8% ±
7.2%, p = ns).
Innervation defects and AF relapses
In the short-term follow-up period of 6 months, four
out of ten patients (40%) with regional innervation de-
fects after PVI suffered from an early recurrence of AF.
In contrast, only one of the six patients (17%) without
detectable regional defects of myocardial 123I-mIBG up-
take after PVI had a clinically apparent early relapse of
AF (Figure 5). In case of the four patients with preexist-
ing and persisting defects, one patient (25%) suffered
from a clinical relapse. However, the mean SDS after
PVI were slightly but not significantly higher in patients
with and AF relapses compared with patients without
relapses (no relapse n = 11:2.4 ± 1.5 vs. relapse n =
4:2.7 ± 3.1; p = ns). The formally calculated sensitivity,Figure 2 Example of a patient with a new innervation defect after PV
injection before and after PVI. Regional late innervation deficit/increased re
arrow). Increasing SDS (summed defect score) but Stable H/M ratio.specificity, positive predictive value and negative predict-
ive value were 80%, 45%, 40%, and 83%.
Left atrial volumes and AF relapse
Except one patient, left atrial volumes were calculated
on the basis of contrast enhanced CT data. Patients suf-
fering from a relapse showed a tendency towards larger
left atrial volumes [95 ± 23 ml vs. 132 ± 36 ml (no relapse
vs. relapse; n = 11 vs. 4)]. However, statistical analysis
revealed no significant differences (p = ns).
Left ventricular function and AF relapse
Left ventricular volumes (ESV, EDV) and LVEF were pre-
served in every patient and did not change significantly
after PVI (ESV, pre 36 ± 14 ml vs. post 35 ± 15 ml; EDV, pre
107 ± 24 ml vs. post 102 ± 28 ml; LVEF, pre 66% ± 7% vs.
post 67% ± 9%; all p = ns). These parameters did not differ
between patients without or with AF relapse either [ESV,
37 ± 10 ml vs. 33 ± 20 ml; EDV, 106 ± 19 ml vs. 108 ±
44 ml; LVEF, 65% ± 6% vs. 70% ± 7%; all p = ns (no relapse
vs. relapse; n = 11 vs. 4)].
Discussion
PVI causes changes in cardiac sympathetic innervation
Solid evidence supports the hypothesis that the sympa-
thetic cardiac nervous system plays a key role in the
initiation and propagation of cardiac arrhythmias includ-
ing paroxysmal AF [19-22]. Data from animal studies
suggest that sympathetic innervation changes lead to
alterations rendering the atrium more vulnerable to the
arrhythmogenic triggers originating from the pulmonary
veins [23-26]. Recently, Akutsu et al. performed a cardiac
123I-mIBG study in patients with paroxysmal AF [8].
They found that a reduced H/M ratio was a powerfulI. Short axis slices of the left ventricle 15 min and 4 h after 123I-mIBG
gional washout after PVI affecting the basal inferolateral wall (white
Figure 3 Development of the SDS (summed defect score) in the
individual patients (pre-PVI versus post PVI).
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AF and heart failure plus permanent AF. Arimoto et al.
were the first to perform cardiac 123I-mIBG imaging in
patients with AF after treatment with PVI [9]. In contrast
to our data, they reported a high WR as an independent
predictor of AF recurrence in patients with paroxysmal
or permanent AF, a finding which is possibly missed by
our study due to the size of the patient cohort. On the
contrary, a subgroup of 20 patients underwent 123I-mIBG
imaging before and after PVI. In this group neither the
H/M ratio nor the global WR changed significantly after
treatment. This finding is in line with our results, but in
contrast to the study by Arimoto et al. [9], we addition-
ally assessed segmental tracer uptake known to improve
the sensitivity and specificity of the imaging technique
[27]. Hence, we observed regionally increased washout
and reduced late segmental 123I-mIBG uptake in 25% of
the patients already before PVI and newly emerging in-
nervation defects in 37.5% of patients after PVI.
Changes in sympathetic innervation are located in the
posterolateral wall
123I-mIBG SPECT/CT analysis shows that the regional de-
fects are located in the inferior lateral wall of the left ven-
tricle, both before and after PVI, but more frequently after
PVI. Interestingly, while atrial ganglionated plexuses seem
to be located in multiple locations on atrial chamber walls
[21], different studies suggest that ventricular ganglionated
plexuses appear to be primarily associated with the origins
of major cardiac blood vessels. In addition, there is a high
density of nerves near the venous ostia and along the pul-
monary veins. Various anatomical studies (reviewed in
[21]) implicate that these nerves appear to originate in the
ganglionated plexuses along the middle and dorsum of the
right atrium, while the corresponding nerve endings seem
to penetrate mostly at the root of the veins.
As a firstly intriguing explanation, the observed innerv-
ation defects could be interpreted as a consequence of
direct denervation due to ablation of sympathetic nervefibers around the pulmonary veins similar to the results of
a study performed by Mabucchi et al. [28]. These authors
described a partial left ventricular sympathetic denervation
assessed by cardiac 123I-mIBG imaging after mitral valve
surgery. Alternatively, the degree of rhythm control follow-
ing PVI might offer another interpretation of our results.
In this model, the interplay between sinus rhythm and
atrial fibrillation episodes alters sympathetic innervation
and therefore leads to regional innervation imbalances.
More specifically, the occurrence of paroxysmal AF with
short duration may cause the appearance of regional
denervation. Hence, ventricular innervation imbalances
may reflect primarily atrial innervation imbalances.
Regional changes in sympathetic innervation affect both
uptake and washout
The results from our study show convincingly that the
changes in sympathetic innervation affect both uptake
and washout. A number of studies dealing with cardiac
123I-mIBG imaging in several cardiac diseases have
noted decreased global cardiac 123I-mIBG uptake (H/M
ratio) in combination with increased global washout. In
a variety of different conditions such as congestive heart
failure, coronary artery disease, and inherited arrhyth-
mias, such changes have been demonstrated to indicate
disease progression or an adverse prognosis [8,29-35].
Additionally, pharmaceutical and device therapy in
some of these conditions has resulted in recession of
these findings [36-38]. The fact that different cardiac
diseases are associated with the changes in cardiac up-
take or washout of 123I-mIBG suggests the presence of a
common reaction of the cardiac sympathetic nervous
system [39]. It has been suggested that one such mech-
anism could be a high rate of post-ganglionic cardiac
sympathetic traffic whereby the locally increased rate
of translocation of neurotransmitter vesicles to the
membrane surface and an increased rate of exocytosis
result in decreased regional 123I-mIBG uptake and
higher washout. The results of our study point to the
development of regional imbalances of sympathetic
innervation with either increased regional sympathetic
tone (reflected by the increased regional washout) or
innervation defects in patients with PAF (paroxysmal
atrial fibrillation) both before and after PVI.
Since sympathetic innervation is considered to be a
highly dynamic process with an ability to self-regenerate
[28], the findings suggest that the cardiac sympathetic
nervous system might play a role both in the remodel-
ing process that is associated with paroxysmal AF and
the reverse remodeling following PVI. Thus, the remod-
eling process of the sympathetic nervous system might
have an impact on the likelihood to develop an AF re-
lapse in the short-term course following PVI. Clinical
studies indicate that this period of time is crucial for the
Figure 4 Quantitative 17-segmental analysis. Quantitative 17-segmental analysis of the late 123I-mIBG uptake (left) and washout (right) of the
left ventricle before (A) and after (B) PVI. Values are expressed as mean regional uptake in comparison to the regional maximum uptake and
segmental washout (%). Significantly reduced uptake and increased regional washout after PVI (mean values after PVI compared with mean values
before PVI) in the basal inferior and basal lateral segments (C).
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probability of sinus rhythm maintenance [2,40-42]. In
patients with more intense atrial remodeling the remod-
eling process may result in a more extensive sympa-
thetic damage and subsequently to more severe left
ventricular denervation.
Regional sympathetic innervation deficits might help
identify patients at risk for AF relapse
Hence, we hypothesize that regional defects of cardiac
123I-mIBG uptake and increased regional washout arehallmarks of sympathetic innervation imbalances, which
may be useful parameters for the non-invasive risk strati-
fication of AF occurrences. Although based on findings
in a relatively small patient cohort the results of our
study suggest a certain prognostic value of 123I-mIBG
SPECT/CT. As the absence of innervation deficits was
indicative for a better outcome with respect to the occur-
rence of AF relapses, the negative predictive value of
123I-mIBG SPECT/CT may be high, a preliminary finding
which has to be interpreted with caution and has to be
proved in a larger patient cohort. Apart from that,
Figure 5 Number of relapses in patients without (1/6) and with
(4/10) innervation deficits post PVI.
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AF relapses following PVI [40,41]. Accordingly, patients
with AF relapses in our study tended to have larger left
atrial volumes. However, the differences in atrial size in
comparison to patients without AF relapse did not reach
the level of statistical significance.
Left ventricular function was preserved in our patient
cohort, did not change after PVI, and did not correlate
with AF relapses. Therefore, our imaging results should
not be confounded by the presence of heart failure.
Moreover, relevant coronary artery disease was excluded
in our patient cohort.
Further studies with larger patient cohorts are needed
to clarify the value of 123I-mIBG SPECT/CT for risk strati-
fication and adequate patient selection of AF patients for
PVI. It remains to be determined whether regional sympa-
thetic innervation deficits are a surrogate parameter for
incomplete PVI with respect to the middle and/or long-
term outcome. In addition, further research is necessary
to decipher the effect of cardiac sympathetic innervation
inhomogeneity on susceptibility to AF in patients suffering
from AF paroxysms and on AF relapses in patients follow-
ing PVI.
Limitations
This observational study does not contain data from a
control group treated without PVI, since we compare
cardiac innervation status before PVI with that after PVI.
Beyond patient-related issues, the imaging method chosen
in this clinical study allows for ventricular imaging only,
since due to the low mass of the atria only left ventricular
innervation can be assessed and local sympathetic innerv-
ation changes around the pulmonary veins could not be
adequately measured.
Measurements of left atrial volumes are not exact
since the majority of CT scans were performed non-
ECG-triggered.Conclusions
A significant number of patients with paroxysmal AF
show regional sympathetic innervation deficits already
before PVI. In addition, PVI is obviously associated with
newly emerging regional cardiac innervation defects
mainly observed in the inferior lateral wall. However, it
is yet unclear whether these regional changes in the
cardiac sympathetic innervation arise from an atrophy of
sympathetic nerve plexus due to PVI or whether they
can be attributed to a significant reduction of AF burden
after PVI. Moreover, although in a small set of patients,
the absence of innervation defects may be an indicator
for a better outcome and the presence of regional
innervation defects after PVI may be indicative for the
risk of AF relapses. In summary, cardiac sympathetic
innervation seems to play a role in AF and PVI. Larger
prospective studies are needed to clarify these issues.
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